|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
VETOES
|
|
|
|
|
S.B. 909
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(f) The Task Force shall:
(1) identify the costs of autoimmune disease that have been incurred by
the State and study potential ways to reduce the costs;
(2) identify benefits to the citizens of the State of research and medical
work conducted at the National Institutes of Health, the University of Maryland
Medical Center, and the Johns Hopkins Hospital and Health System in Maryland on
autoimmune disease and study ways to improve the benefits to the public and the
professional health community;
(3) identify the services available in the State for people with
autoimmune disease and the gap in services, including duplication and
fragmentation;
(4) study the level of coordination or lack of coordination among State
agencies, State health services, and private health services;
(5) identify the need for training on autoimmune disease for State and
local health departments and explore collaboration with State universities and the
National Institutes of Health to implement such training;
(6) identify ways for the local health departments to integrate the most
advanced autoimmune disease diagnostic techniques and treatments into their health
services;
(7) identify the need for a public awareness campaign on autoimmune
disease in the State to encourage early diagnosis and treatment to lower the cost of
autoimmune disease, and explore ways that such a campaign could be funded and
implemented;
(8) identify ways to link autoimmune patients with health services in the
State;
(9) identify collaborations with the business community and employers
on the long—term and chronic effects of autoimmune disease and ways to assist
employees affected by autoimmune disease;
(10) identify the special needs of women with autoimmune disease and
ways to assist them;
(11) identify private and public funding resources to support future
planning and implementation of the Task Force recommendations;
(12) identify ways for the State to work collaboratively with existing
private resources in the State, such as autoimmune disease patient groups,
professional health associations, health maintenance organizations, hospitals, and
the medical research and biotechnology research communities; and
(13) study other topics relating to autoimmune disease in the State.
|
|
|
|
|
|
|
|
|
|
- 3950 -
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
